Ligand Pharmaceuticals (NASDAQ:LGND) Stock: Insider John Kozarich Sells 500 Shares

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director John Kozarich sold 500 shares of the company’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $325.00, for a total transaction of $162,500.00. Following the transaction, the director owned 42,122 shares in the company, valued at $13,689,650. This represents a 1.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ligand Pharmaceuticals Stock Performance

Shares of NASDAQ LGND traded down $7.08 during trading on Monday, reaching $301.71. 186,903 shares of the company traded hands, compared to its average volume of 263,991. The firm has a 50 day simple moving average of $301.71 and a 200-day simple moving average of $258.02. Ligand Pharmaceuticals Incorporated has a 52-week low of $175.89 and a 52-week high of $326.63. The stock has a market capitalization of $6.04 billion, a PE ratio of 134.69, a P/E/G ratio of 5.39 and a beta of 1.16. The company has a quick ratio of 1.19, a current ratio of 1.22 and a debt-to-equity ratio of 0.71.

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.34. The firm had revenue of $78.75 million during the quarter, compared to analysts’ expectations of $77.00 million. Ligand Pharmaceuticals had a net margin of 20.27% and a return on equity of 5.22%. The firm’s quarterly revenue was down 31.8% on a year-over-year basis. During the same period in the previous year, the company earned $3.09 earnings per share. Equities research analysts anticipate that Ligand Pharmaceuticals Incorporated will post 2.35 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on LGND shares. Citigroup boosted their target price on shares of Ligand Pharmaceuticals from $397.00 to $402.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Weiss Ratings downgraded Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a research note on Monday, November 2nd. Leerink Partners initiated coverage on Ligand Pharmaceuticals in a report on Friday, August 14th. They issued an “outperform” rating and a $330.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $358.00 price objective on shares of Ligand Pharmaceuticals in a research report on Thursday, September 24th. Finally, Barclays increased their target price on Ligand Pharmaceuticals from $345.00 to $350.00 and gave the company an “overweight” rating in a report on Wednesday, November 11th. Eight investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Ligand Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $355.38.

Get Our Latest Stock Report on Ligand Pharmaceuticals

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC bought a new stake in shares of Ligand Pharmaceuticals during the 2nd quarter valued at $27,000. Jacobi Capital Management LLC bought a new position in Ligand Pharmaceuticals in the 3rd quarter worth $31,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Ligand Pharmaceuticals in the 2nd quarter worth $75,000. MCF Advisors LLC lifted its position in Ligand Pharmaceuticals by 118.9% during the second quarter. MCF Advisors LLC now owns 243 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 132 shares in the last quarter. Finally, Covestor Ltd lifted its position in Ligand Pharmaceuticals by 49.8% during the third quarter. Covestor Ltd now owns 337 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 112 shares in the last quarter. 91.28% of the stock is currently owned by institutional investors.

About Ligand Pharmaceuticals

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

Read More

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.